» Articles » PMID: 37706180

CT Radiomics Model for Predicting the Ki-67 Proliferation Index of Pure-solid Non-small Cell Lung Cancer: a Multicenter Study

Overview
Journal Front Oncol
Specialty Oncology
Date 2023 Sep 14
PMID 37706180
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This study aimed to explore the efficacy of the computed tomography (CT) radiomics model for predicting the Ki-67 proliferation index (PI) of pure-solid non-small cell lung cancer (NSCLC).

Materials And Methods: This retrospective study included pure-solid NSCLC patients from five centers. The radiomics features were extracted from thin-slice, non-enhanced CT images of the chest. The minimum redundancy maximum relevance (mRMR) and least absolute shrinkage and selection operator (LASSO) were used to reduce and select radiomics features. Logistic regression analysis was employed to build predictive models to determine Ki-67-high and Ki-67-low expression levels. Three prediction models were established: the clinical model, the radiomics model, and the nomogram model combining the radiomics signature and clinical features. The prediction efficiency of different models was evaluated using the area under the curve (AUC).

Results: A total of 211 NSCLC patients with pure-solid nodules or masses were included in the study (N=117 for the training cohort, N=49 for the internal validation cohort, and N=45 for the external validation cohort). The AUC values for the clinical models in the training, internal validation, and external validation cohorts were 0.73 (95% CI: 0.64-0.82), 0.75 (95% CI:0.62-0.89), and 0.72 (95% CI: 0.57-0.86), respectively. The radiomics models showed good predictive ability in diagnosing Ki-67 expression levels in the training cohort (AUC, 0.81 [95% CI: 0.73-0.89]), internal validation cohort (AUC, 0.81 [95% CI: 0.69-0.93]) and external validation cohort (AUC, 0.78 [95% CI: 0.64-0.91]). Compared to the clinical and radiomics models, the nomogram combining both radiomics signatures and clinical features had relatively better diagnostic performance in all three cohorts, with the AUC of 0.83 (95% CI: 0.76-0.90), 0.83 (95% CI: 0.71-0.94), and 0.81 (95% CI: 0.68-0.93), respectively.

Conclusion: The nomogram combining the radiomics signature and clinical features may be a potential non-invasive method for predicting Ki-67 expression levels in patients with pure-solid NSCLC.

Citing Articles

CT-based radiomics for predicting Ki-67 expression in lung cancer: a systematic review and meta-analysis.

Luo X, Zheng R, Zhang J, He J, Luo W, Jiang Z Front Oncol. 2024; 14:1329801.

PMID: 38384802 PMC: 10879429. DOI: 10.3389/fonc.2024.1329801.

References
1.
Li Z, Li F, Pan C, He Z, Pan X, Zhu Q . Tumor cell proliferation (Ki-67) expression and its prognostic significance in histological subtypes of lung adenocarcinoma. Lung Cancer. 2021; 154:69-75. DOI: 10.1016/j.lungcan.2021.02.009. View

2.
Winther-Larsen A, Demuth C, Fledelius J, Madsen A, Hjorthaug K, Meldgaard P . Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients. Br J Cancer. 2017; 117(5):704-709. PMC: 5572172. DOI: 10.1038/bjc.2017.215. View

3.
Werynska B, Pula B, Muszczynska-Bernhard B, Piotrowska A, Jethon A, Podhorska-Okolow M . Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer. Anticancer Res. 2011; 31(9):2833-9. View

4.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

5.
Marchevsky A, Hendifar A, Walts A . The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence. Mod Pathol. 2018; 31(10):1523-1531. DOI: 10.1038/s41379-018-0076-9. View